Literature DB >> 32026360

Naturally Occurring Antibodies to Tau Exists in Human Blood and Are Not Changed in Alzheimer's Disease.

Zhong-Yuan Yu1,2, Wei-Wei Li1, Hai-Mei Yang1, Noralyn B Mañucat-Tan3, Jun Wang1, Ye-Ran Wang1, Bin-Lu Sun1, Zi-Cheng Hu1, Li-Li Zhang1, Liang Tan4, Juan Deng5, Yu-Hui Liu6.   

Abstract

Hyperphosphorylated tau is an important pathological agent in Alzheimer's disease (AD). Tau effluxes from the brain to the blood could potentially stimulate the production of naturally occurring antibodies (NAbs). We aimed to investigate whether NAbs to tau (NAbs-tau) was generated in human blood and to figure out the alteration of plasma NAbs-tau level in AD patients. About 192 AD patients and 192 age-matched and non-demented controls (NC) were enrolled in the present study. Immunofluorescence staining and western blot assays were used to confirm the existence of NAbs-tau in human blood. The plasma level of NAbs-tau in NC and AD group was analyzed by ELISA. Immunofluorescence staining and western blot assays confirmed the existence of NAbs-tau in human blood. However, no significant difference in the plasma level of NAbs-tau was observed between NC and AD group. Furthermore, the plasma level of NAbs-tau had no significant correlation with MMSE scores. The present study confirmed that NAbs-tau exists in human blood but does not differ in level between the NC and AD group. Plasma NAbs-tau is not a reliable biomarker for AD.

Entities:  

Keywords:  Alzheimer’s disease; Biomarker; Naturally occurring antibodies to tau; Tau

Year:  2020        PMID: 32026360     DOI: 10.1007/s12640-020-00161-9

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  25 in total

Review 1.  Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies.

Authors:  Yu-Hui Liu; Fan Zeng; Ye-Ran Wang; Hua-Dong Zhou; Brian Giunta; Jun Tan; Yan-Jiang Wang
Journal:  Drug Discov Today       Date:  2013-08-13       Impact factor: 7.851

2.  Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy.

Authors:  Kiran Yanamandra; Tirth K Patel; Hong Jiang; Suzanne Schindler; Jason D Ulrich; Adam L Boxer; Bruce L Miller; Diana R Kerwin; Gilbert Gallardo; Floy Stewart; Mary Beth Finn; Nigel J Cairns; Philip B Verghese; Ilana Fogelman; Tim West; Joel Braunstein; Grace Robinson; Jennifer Keyser; Joseph Roh; Stephanie S Knapik; Yan Hu; David M Holtzman
Journal:  Sci Transl Med       Date:  2017-04-19       Impact factor: 17.956

3.  Associations Between ApoEε4 Carrier Status and Serum BDNF Levels--New Insights into the Molecular Mechanism of ApoEε4 Actions in Alzheimer's Disease.

Authors:  Yu-Hui Liu; Shu-Sheng Jiao; Ye-Ran Wang; Xian-Le Bu; Xiu-Qing Yao; Yang Xiang; Qing-Hua Wang; Lin Wang; Juan Deng; Jing Li; Xin-Fu Zhou; Hua-Dong Zhou; Yan-Jiang Wang
Journal:  Mol Neurobiol       Date:  2014-07-02       Impact factor: 5.590

4.  Detection of circulating antibodies against tau protein in its unphosphorylated and in its neurofibrillary tangles-related phosphorylated state in Alzheimer's disease and healthy subjects.

Authors:  Hanna Rosenmann; Zeev Meiner; Valeria Geylis; Oded Abramsky; Michael Steinitz
Journal:  Neurosci Lett       Date:  2006-12-20       Impact factor: 3.046

Review 5.  Etiology and pathogenesis of late-onset Alzheimer's disease.

Authors:  Brian J Balin; Alan P Hudson
Journal:  Curr Allergy Asthma Rep       Date:  2014-03       Impact factor: 4.806

6.  Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament.

Authors:  Ales Bartos; Lenka Fialová; Jana Svarcová; Daniela Ripova
Journal:  J Neuroimmunol       Date:  2012-09-02       Impact factor: 3.478

7.  The ProNGF/p75NTR pathway induces tau pathology and is a therapeutic target for FTLD-tau.

Authors:  Lin-Lin Shen; Noralyn B Mañucat-Tan; Shi-Hao Gao; Wei-Wei Li; Fan Zeng; Chi Zhu; Jun Wang; Xian-Le Bu; Yu-Hui Liu; Chang-Yue Gao; Zhi-Qiang Xu; Larisa Bobrovskaya; Peng Lei; Jin-Tai Yu; Weihong Song; Hua-Dong Zhou; Xiu-Qing Yao; Xin-Fu Zhou; Yan-Jiang Wang
Journal:  Mol Psychiatry       Date:  2018-06-04       Impact factor: 15.992

8.  Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models.

Authors:  Sethu Sankaranarayanan; Donna M Barten; Laurel Vana; Nino Devidze; Ling Yang; Gregory Cadelina; Nina Hoque; Lynn DeCarr; Stefanie Keenan; Alan Lin; Yang Cao; Bradley Snyder; Bin Zhang; Magdalena Nitla; Gregg Hirschfeld; Nestor Barrezueta; Craig Polson; Paul Wes; Vangipuram S Rangan; Angela Cacace; Charles F Albright; Jere Meredith; John Q Trojanowski; Virginia M-Y Lee; Kurt R Brunden; Michael Ahlijanian
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

9.  Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia.

Authors:  Yannick Kronimus; Alexandra Albus; Monika Balzer-Geldsetzer; Sarah Straub; Elisa Semler; Markus Otto; Jens Klotsche; Richard Dodel; David Mengel
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

Review 10.  Current state of Alzheimer's fluid biomarkers.

Authors:  José Luis Molinuevo; Scott Ayton; Richard Batrla; Martin M Bednar; Tobias Bittner; Jeffrey Cummings; Anne M Fagan; Harald Hampel; Michelle M Mielke; Alvydas Mikulskis; Sid O'Bryant; Philip Scheltens; Jeffrey Sevigny; Leslie M Shaw; Holly D Soares; Gary Tong; John Q Trojanowski; Henrik Zetterberg; Kaj Blennow
Journal:  Acta Neuropathol       Date:  2018-11-28       Impact factor: 17.088

View more
  2 in total

Review 1.  Peripheral Pathways to Neurovascular Unit Dysfunction, Cognitive Impairment, and Alzheimer's Disease.

Authors:  Amy R Nelson
Journal:  Front Aging Neurosci       Date:  2022-04-18       Impact factor: 5.702

Review 2.  The Functional Roles and Applications of Immunoglobulins in Neurodegenerative Disease.

Authors:  Kyu-Young Sim; Kyeong Chan Im; Sung-Gyoo Park
Journal:  Int J Mol Sci       Date:  2020-07-26       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.